This is a single arm, phase II trial of HLA-haploidentical related hematopoietic cells
transplant (Haplo-HCT) using reduced intensity conditioning (fludarabine and melphalan and
total body irradiation). Peripheral blood is the donor graft source. This study is designed
to estimate disease-free survival (DFS) at 18 months post-transplant.
Total body irradiation
Clinical Study Identifier
H. Lee Moffitt Cancer Center and Research Institute
Last Modified on
4 November 2020
How clear was the trial content above?
Adding a note
Select a piece of text and start making personal notes.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.